Dipeptidyl Peptidase-4 inhibitor (Vildagliptin) induced oral mucositis: A case report

Diabetes Metab Syndr. 2021 Mar-Apr;15(2):509-511. doi: 10.1016/j.dsx.2021.02.011. Epub 2021 Feb 13.

Authors

Prasanth Sankar¹, Soumya Jagadeesan², Waseem N Ahmed³

Affiliations

¹ MGM Muthoot Hospitals Pathanamthitta, Kerala, India.
² Dept of Dermatology, Amrita Institute of Medical Sciences, Kerala, India.
³ Department of Family and Internal Medicine, CRAFT Hospital and Research Centre, Kerala, India. Electronic address: researchin2017@gmail.com.

PMID: 33662838
DOI: 10.1016/j.dsx.2021.02.011

No abstract available

Keywords: Adverse reaction; DPP-4 inhibitor; Diabetes management; Oral ulcer; Vildagliptin.

Publication types

Case Reports

MeSH terms

Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / drug therapy
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
Female
Humans
Hypoglycemic Agents / adverse effects*
Hypoglycemic Agents / therapeutic use
Middle Aged
Mouth Mucosa / pathology
Stomatitis / chemically induced*
Stomatitis / pathology
Stomatitis / therapy
Vildagliptin / adverse effects*
Vildagliptin / therapeutic use

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Vildagliptin